Immunohistochemistry (IHC) : Formalin-fixed, paraffin-embedded human liposarcoma stained with anti-CDK4 antibody using peroxidase-conjugate and DAB chromogen. Note nuclear/cytoplasmic staining of tumor cells.

rabbit anti-CDK4 monoclonal antibody (ZR394) 6118

Price range: $160.00 through $528.00

Antibody summary

Rabbit monoclonal to CDK4
Suitable for: Immunohistochemistry (formalin-fixed, paraffin-embedded tissues)
Reacts with: Human
Isotype:IgG
Control: Urothelial carcinoma, well-differentiated liposarcoma
Visualization: Nucleus and cytoplasm
0.1, 0.5, 1.0 mL concentrated, 7 mL prediluted

available sizes

Clear

SKU: 6118parent Category: antibody Tags: anatomy, CDK4, Soft Tissue Pathology

Weight	1 lbs
Dimensions	9 × 5 × 2 in
host	mouse
isotype	IgG
clonality	monoclonal
concentration	concentrate, predilute
applications	IHC
reactivity	human
available size	0.1 mL, 0.5 mL, 1 mL concentrated, 7 mL prediluted

rabbit anti-CDK4 monoclonal antibody ZR394 6118

antibody
Database link: human P11802
Tested applications IHC
Recommended dilutions Concentrated 1:100-200
Application Notes Positive control: Urothelial carcinoma, well-differentiated liposarcoma
Immunogen Recombinant fragment corresponding to N-terminal of human CDK4 protein
Size and concentration 7 mL prediluted or 0.1, 0.5, 1.0 mL and concentrated
Form liquid
Storage Instructions 2-8°C for short term, for longer term at -20°C. Avoid freeze / thaw cycles.
Purity affinity purified
Clonality monoclonal
Isotype IgG
Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control Rabbit polyclonal - Isotype Control

target relevance
Protein names Cyclin-dependent kinase 4 (EC 2.7.11.22) (Cell division protein kinase 4) (PSK-J3)
Gene names CDK4,CDK4
Protein family Protein kinase superfamily, CMGC Ser/Thr protein kinase family, CDC2/CDKX subfamily
Mass 33730Da
Function FUNCTION: Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. {ECO:0000269\|PubMed:15241418, ECO:0000269\|PubMed:18827403, ECO:0000269\|PubMed:9003781}.
Catalytic activity CATALYTIC ACTIVITY: Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22; Evidence={ECO:0000269\|PubMed:19075005, ECO:0000269\|PubMed:19237565, ECO:0000269\|PubMed:9106657}; CATALYTIC ACTIVITY: Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.22; Evidence={ECO:0000269\|PubMed:19075005, ECO:0000269\|PubMed:19237565, ECO:0000269\|PubMed:9106657};
Subellular location SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269\|PubMed:18827403}. Nucleus {ECO:0000269\|PubMed:18827403, ECO:0000269\|PubMed:20399237, ECO:0000269\|PubMed:9106657}. Nucleus membrane {ECO:0000269\|PubMed:18827403}. Note=Cytoplasmic when non-complexed. Forms a cyclin D-CDK4 complex in the cytoplasm as cells progress through G(1) phase. The complex accumulates on the nuclear membrane and enters the nucleus on transition from G(1) to S phase. Also present in nucleoli and heterochromatin lumps. Colocalizes with RB1 after release into the nucleus. {ECO:0000269\|PubMed:18827403}.
Structure SUBUNIT: Component of the D-CDK4 complex, composed of CDK4 and some D-type G1 cyclin (CCND1, CCND2 or CCND3). Interacts directly in the complex with CCND1, CCND2 or CCND3. Interacts with SEI1 and ZNF655. Forms a ternary complex, cyclin D-CDK4-CDKN1B, involved in modulating CDK4 enzymatic activity. Interacts directly with CDKN1B (phosphorylated on 'Tyr-88' and 'Tyr-89'); the interaction allows assembly of the cyclin D-CDK4 complex, Thr-172 phosphorylation, nuclear translocation and enhances the cyclin D-CDK4 complex activity. CDK4 activity is either inhibited or enhanced depending on stoichiometry of complex. The non-tyrosine-phosphorylated form of CDKN1B prevents T-loop phosphorylation of CDK4 producing inactive CDK4. Interacts (unphosphorylated form) with CDK2. Also forms ternary complexes with CDKN1A or CDKN2A. Interacts directly with CDKN1A (via its N-terminal); the interaction promotes the assembly of the cyclin D-CDK4 complex, its nuclear translocation and promotes the cyclin D-dependent enzyme activity of CDK4. Interacts with CCND1; the interaction is prevented with the binding of CCND1 to INSM1 during cell cycle progression. Probably forms a complex composed of chaperones HSP90 and HSP70, co-chaperones CDC37, PPP5C, TSC1 and client protein TSC2, CDK4, AKT, RAF1 and NR3C1; this complex does not contain co-chaperones STIP1/HOP and PTGES3/p23 (PubMed:29127155). Interacts with CEBPA (when phosphorylated) (PubMed:15107404). Interacts with FNIP1 and FNIP2 (PubMed:27353360). {ECO:0000250\|UniProtKB:P30285, ECO:0000269\|PubMed:10580009, ECO:0000269\|PubMed:15107404, ECO:0000269\|PubMed:15558030, ECO:0000269\|PubMed:16782892, ECO:0000269\|PubMed:18827403, ECO:0000269\|PubMed:19075005, ECO:0000269\|PubMed:19124461, ECO:0000269\|PubMed:19237555, ECO:0000269\|PubMed:19237565, ECO:0000269\|PubMed:20399237, ECO:0000269\|PubMed:27353360, ECO:0000269\|PubMed:29127155, ECO:0000269\|PubMed:9106657}.
Post-translational modification PTM: Phosphorylation at Thr-172 is required for enzymatic activity. Phosphorylated, in vitro, at this site by CCNH-CDK7, but, in vivo, appears to be phosphorylated by a proline-directed kinase. In the cyclin D-CDK4-CDKN1B complex, this phosphorylation and consequent CDK4 enzyme activity, is dependent on the tyrosine phosphorylation state of CDKN1B. Thus, in proliferating cells, CDK4 within the complex is phosphorylated on Thr-172 in the T-loop. In resting cells, phosphorylation on Thr-172 is prevented by the non-tyrosine-phosphorylated form of CDKN1B. {ECO:0000269\|PubMed:16782892, ECO:0000269\|PubMed:19075005, ECO:0000269\|PubMed:19237555, ECO:0000269\|PubMed:19237565, ECO:0000269\|PubMed:19487459}.
Involvement in disease DISEASE: Melanoma, cutaneous malignant 3 (CMM3) [MIM:609048]: A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but may also involve other sites. {ECO:0000269\|PubMed:7652577, ECO:0000269\|PubMed:8528263, ECO:0000269\|PubMed:9311594, ECO:0000269\|PubMed:9425228}. Note=Disease susceptibility is associated with variants affecting the gene represented in this entry.
Target Relevance information above includes information from UniProt accession: P11802
The UniProt Consortium

Data

Formalin-fixed, paraffin-embedded human liposarcoma stained with anti-CDK4 antibody using peroxidase-conjugate and DAB chromogen. Note nuclear/cytoplasmic staining of tumor cells.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.